Omega Diagnostics Group PLC - AIM Listed

Omega Diagnostics was based on the reverse acquisition in 2007 of an infectious disease business providing high quality In Vitro diagnostic products for use in hospitals, blood banks, clinics and laboratories in over 100 countries - its strategy was to pursue a 'buy & build strategy' by acquiring businesses with products which could leverage this distribution platform. In 2018 the original infectious disease business was sold, leaving the group focusing on three diagnostic areas, namely food intolerance, allergy and HIV.

More detail can be accessed by clicking on Omega on SMARTCO Research under Links in the right hand column.


Omega Diagnostics
Omega on SMARTCO Research

Last Updated: 24/07/2018

Investment Information:
date of first inv: Sep 2007
cost: £328,000
valn at: 30/06/2018 £271,000
equity held: 1.8%